Patient preferences for frontline therapies for Philadelphia chromosome-positive acute lymphoblastic leukemia: a discrete choice experiment

被引:3
|
作者
Ashaye, Ajibade [1 ]
Thomas, Caitlin [2 ]
Dalal, Mehul [1 ]
Kota, Vamsi [3 ]
Krucien, Nicolas [2 ]
Sae-Hau, Maria [4 ]
Weiss, Elisa [4 ]
Campbell, Scott [1 ]
Marsh, Kevin [2 ]
机构
[1] Takeda Dev Ctr Amer Inc, Lexington, MA 02421 USA
[2] Evidera, London W6 8BJ, England
[3] Augusta Univ, Sect Hematol & Oncol, Georgia Canc Ctr, Augusta, GA 30912 USA
[4] Leukemia & Lymphoma Soc, Rye Brook, NY 10573 USA
关键词
acute lymphoblastic leukemia; discrete choice experiment; hematologic neoplasms; patient preference; Philadelphia chromosome; shared decision making; tyrosine kinase inhibitor; CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITORS; TERM-FOLLOW-UP; PONATINIB; DECISIONS; IMATINIB; PHASE-2;
D O I
10.2217/fon-2022-0082
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: We examined the preferences of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) for benefits and risks of tyrosine kinase inhibitors combined with chemotherapy for first-line treatment. Methods: In a discrete choice experiment, 201 patients chose between hypothetical treatment alternatives with varied levels of remission duration and overall survival (OS), and risks of major cardiovascular (CV) events and myelosuppression. Results: Although OS was the most important attribute to patients with Ph+ ALL, they were willing to tolerate a 2.9% increase in CV risk for 1 additional month of OS. Older patients (>59 years) and patients not in remission were less likely to tolerate increased CV risk. Conclusion: Preferences and risk tolerance varied between patients, highlighting the importance of shared decision making when selecting treatments for Ph+ ALL. Plain language summary Treatments differ in their potential benefits and side effects they may come with. Patients should be involved in deciding which treatments they receive. This is because patients may have different views than physicians on how the benefits and side effects of treatment would affect their quality of life. Additionally, patients may have different risk tolerances. This study shows how patients with a form of leukemia valued survival benefits and side effects of treatments, and the trade-offs that they were willing to make between these. On average, longer survival had most value to patients. They were willing to accept a higher risk of a major cardiovascular side effect (e.g., having a stroke) if the treatment would allow them to live longer. However, not all patients had the same opinion, and some groups of patients were less willing to accept risks to receive longer survival. By involving patients in treatment decisions, we can help ensure they receive treatments that match their personal preferences.
引用
收藏
页码:2075 / 2085
页数:11
相关论文
共 50 条
  • [1] Targeted therapies in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia
    Hoelzer, D
    Gökbuget, N
    Ottmann, OG
    [J]. SEMINARS IN HEMATOLOGY, 2002, 39 (04) : 32 - 37
  • [2] Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Jabbour, Elias
    Kantarjian, Hagop M.
    Aldoss, Ibrahim
    Montesinos, Pau
    Leonard, Jessica T.
    Gomez-Almaguer, David
    Baer, Maria R.
    Gambacorti-Passerini, Carlo
    McCloskey, James
    Minami, Yosuke
    Papayannidis, Cristina
    Rocha, Vanderson
    Rousselot, Philippe
    Vachhani, Pankit
    Wang, Eunice S.
    Wang, Bingxia
    Hennessy, Meliessa
    Vorog, Alexander
    Patel, Niti
    Yeh, Tammie
    Ribera, Jose-Maria
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2024, 331 (21): : 1814 - 1823
  • [3] Philadelphia chromosome-positive Acute Lymphoblastic Leukemia
    Forghieri, Fabio
    Luppi, Mario
    Potenza, Leonardo
    [J]. HEMATOLOGY, 2015, 20 (10) : 618 - 619
  • [4] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Ravandi, Farhad
    Kebriaei, Partow
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2009, 23 (05) : 1043 - +
  • [5] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Foa, Robin
    Chiaretti, Sabina
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25): : 2399 - 2411
  • [6] Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Hanane, W.
    Siham, C.
    [J]. PEDIATRIC BLOOD & CANCER, 2019, 66 : S312 - S312
  • [7] Philadelphia chromosome-positive acute lymphoblastic leukemia in children
    Oki, Y
    Kishi, Y
    Kami, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (14): : 1043 - 1043
  • [8] PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC-LEUKEMIA
    LESTINGI, TM
    HOOBERMAN, AL
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1993, 7 (01) : 161 - 175
  • [9] Treatment of Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Fielding, A. K.
    Zakout, G. A.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (02) : 98 - 108
  • [10] Approach to Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
    Haddad, Fadi G.
    Kantarjian, Hagop
    Jabbour, Elias
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S39 - S41